Answer
Rybrevant (amivantamab) is indicated as monotherapy for adults with advanced non-small cell lung cancer with activating EGFR Exon 20 insertion mutations after failure of platinum-based therapy.
Sources for this answer
- Rybrevant (amivantamab) 350mg concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.1 Therapeutic Indications · Version 11Document updated
Sources checked